Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine

Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford–AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threat...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkoumy, Mohammed, Schoen, Julika, Loew, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Adverse drug reactions and complications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096475/
https://www.ncbi.nlm.nih.gov/pubmed/35545306
http://dx.doi.org/10.1136/bcr-2021-246770
_version_ 1784705986553970688
author Elkoumy, Mohammed
Schoen, Julika
Loew, Andreas
author_facet Elkoumy, Mohammed
Schoen, Julika
Loew, Andreas
author_sort Elkoumy, Mohammed
collection PubMed
description Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford–AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threatening complication called vaccine-induced thrombotic thrombocytopenia (VITT) was reported. As the number of cases increases every day, with the increase in the number of vaccinated people all over the world, this complication is a concern to the medical field. We report a case on the acute management of a patient who presented to us with life-threatening bilateral pulmonary embolism as a complication of VITT after the first dose of vaccination with Oxford–AstraZeneca vaccine against COVID-19.
format Online
Article
Text
id pubmed-9096475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90964752022-05-27 Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine Elkoumy, Mohammed Schoen, Julika Loew, Andreas BMJ Case Rep Case Reports: Adverse drug reactions and complications Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford–AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threatening complication called vaccine-induced thrombotic thrombocytopenia (VITT) was reported. As the number of cases increases every day, with the increase in the number of vaccinated people all over the world, this complication is a concern to the medical field. We report a case on the acute management of a patient who presented to us with life-threatening bilateral pulmonary embolism as a complication of VITT after the first dose of vaccination with Oxford–AstraZeneca vaccine against COVID-19. BMJ Publishing Group 2022-05-11 /pmc/articles/PMC9096475/ /pubmed/35545306 http://dx.doi.org/10.1136/bcr-2021-246770 Text en © BMJ Publishing Group Limited 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Reports: Adverse drug reactions and complications
Elkoumy, Mohammed
Schoen, Julika
Loew, Andreas
Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine
title Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine
title_full Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine
title_fullStr Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine
title_full_unstemmed Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine
title_short Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine
title_sort management of a severe bilateral pulmonary embolism as a complication of vitt following vaccination with astrazeneca covid-19 vaccine
topic Case Reports: Adverse drug reactions and complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096475/
https://www.ncbi.nlm.nih.gov/pubmed/35545306
http://dx.doi.org/10.1136/bcr-2021-246770
work_keys_str_mv AT elkoumymohammed managementofaseverebilateralpulmonaryembolismasacomplicationofvittfollowingvaccinationwithastrazenecacovid19vaccine
AT schoenjulika managementofaseverebilateralpulmonaryembolismasacomplicationofvittfollowingvaccinationwithastrazenecacovid19vaccine
AT loewandreas managementofaseverebilateralpulmonaryembolismasacomplicationofvittfollowingvaccinationwithastrazenecacovid19vaccine

Ejemplares similares